PMID- 36961957
OWN - NLM
STAT- MEDLINE
DCOM- 20230328
LR  - 20230426
IS  - 0890-9091 (Print)
IS  - 0890-9091 (Linking)
VI  - 37
IP  - 3
DP  - 2023 Mar 21
TI  - Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review 
      and Meta-analysis.
PG  - 130-141
LID - 10.46883/2023.25920987 [doi]
AB  - BACKGROUND: Mitogen-activated protein kinase (MEK) inhibitors, which integrate 
      the important signaling chain of the RAS-RAF-MEK-ERK1/2 pathway, regulate cell 
      functions such as division and proliferation for patients with solid tumors. 
      However, various ocular adverse effects (AEs) affect patients during clinical 
      treatment. This systematic review aimed to assess the occurrence of AEs during 
      treatment with MEK inhibitors plus targeted therapy or chemotherapy. METHODS: A 
      scientific literature search was conducted in PubMed, the Cochrane Library, 
      Embase, and several Chinese databases to identify randomized controlled trials. 
      Overall, ocular AEs were assessed as the primary end point; blurred vision, 
      chorioretinopathy, and retinal detachment were assessed as secondary end points. 
      RESULTS: Seventeen randomized controlled trials were included. Overall, the use 
      of MEK inhibitors combined with other targeted inhibitors or chemotherapy was 
      significantly associated with a nearly 7.3% increased risk of overall ocular 
      toxicities vs therapy without MEK inhibitors (risk ratio [RR], 2.88; 95% CI, 
      1.42-5.85, P < .05). An increased risk of blurred vision (RR, 4.10; 95% CI, 2.55- 
      6.58; P < .05), chorioretinopathy (RR, 8.36; 95% CI, 3.42-20.47; P < .05), and 
      retinal detachment (RR, 8.98; 95% CI, 3.92-20.57; P < .05) was demonstrated. 
      CONCLUSIONS: Treatment with MEK inhibitors combined with targeted drugs or 
      chemotherapy seems to increase overall ocular AEs. A more practical algorithm for 
      the screening of ocular AEs was suggested to be conducted whenever new or 
      worsening ocular toxicities occur.
FAU - Han, Jing
AU  - Han J
FAU - Chen, Juejing
AU  - Chen J
FAU - Zhou, Hanqiong
AU  - Zhou H
FAU - Hao, Lidan
AU  - Hao L
FAU - Wang, Qiming
AU  - Wang Q
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Oncology (Williston Park)
JT  - Oncology (Williston Park, N.Y.)
JID - 8712059
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinases)
SB  - IM
CIN - Oncology (Williston Park). 2023 Mar 21;37(3):138-139. PMID: 37094287
MH  - Humans
MH  - *Retinal Detachment/chemically induced/drug therapy
MH  - *Neoplasms/drug therapy
MH  - Protein Kinase Inhibitors/adverse effects
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Mitogen-Activated Protein Kinase Kinases
EDAT- 2023/03/25 06:00
MHDA- 2023/03/28 17:16
CRDT- 2023/03/24 15:00
PHST- 2023/03/28 17:16 [medline]
PHST- 2023/03/24 15:00 [entrez]
PHST- 2023/03/25 06:00 [pubmed]
AID - 25920987 [pii]
AID - 10.46883/2023.25920987 [doi]
PST - ppublish
SO  - Oncology (Williston Park). 2023 Mar 21;37(3):130-141. doi: 
      10.46883/2023.25920987.